Ipamorelin Research Compound
Research Use Only
This product is intended for laboratory research purposes only. It is not intended for human or veterinary use, food, cosmetic, household, or agricultural applications. Not for human consumption.
Overview
Ipamorelin is a synthetic pentapeptide growth hormone releasing peptide (GHRP) developed by Novo Nordisk. It is notable for its high selectivity in stimulating growth hormone release from the pituitary without significantly affecting cortisol, ACTH, prolactin, or appetite—side effects commonly seen with other GHRPs like GHRP-6. This selectivity makes Ipamorelin valuable for research requiring isolated GH pathway study.
Molecular Characteristics
| Property | Value |
|---|---|
| Molecular Formula | C38H49N9O5 |
| Molecular Weight | 711.85 g/mol |
| CAS Number | 170851-70-4 |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Amino Acids | 5 |
| Purity | ≥99% (HPLC) |
| Storage | -20°C, protected from light |
Mechanism of Action
Ipamorelin acts through selective ghrelin receptor (GHS-R1a) activation:
GH Release
- Ghrelin receptor agonism
- Somatotroph stimulation
- Dose-dependent GH release
- Pulsatile pattern preservation
Selectivity Profile
- Minimal cortisol stimulation
- No significant prolactin release
- Reduced appetite stimulation (vs. GHRP-6)
- Isolated GH pathway activation
Synergistic Action
- Enhanced effect with GHRH analogs
- Complementary receptor pathways
- Amplified GH pulse amplitude
- Maintained feedback sensitivity
Research Applications
Selective GH Studies
- Isolated GH pathway research
- Side effect profile comparison
- Receptor selectivity studies
- Dose-response characterization
Combined Peptide Research
- GHRH + GHRP synergy (CJC-1295 + Ipamorelin)
- Timing optimization studies
- Comparative efficacy analysis
- Protocol development
Body Composition Research
- Lean mass studies
- Fat metabolism research
- Age-related changes
- Recovery protocols
Safety Profile Research
- Cortisol axis preservation
- Prolactin level monitoring
- Long-term administration studies
- Comparative safety analysis
Available Formats
| Size | Format | Catalog Code |
|---|---|---|
| 2mg | Lyophilized | IPA-2 |
| 5mg | Lyophilized | IPA-5 |
| 10mg | Lyophilized | IPA-10 |
Handling & Storage
- Store lyophilized peptide at -20°C
- Protect from light and moisture
- Reconstitute with bacteriostatic water
- Reconstituted solution stable at 2-8°C for up to 4 weeks
- Avoid repeated freeze-thaw cycles
Quality Specifications
- Purity: ≥99% by HPLC
- Appearance: White lyophilized powder
- Solubility: Soluble in water
- Endotoxin: Less than 1 EU/mg
- Certificate of Analysis provided
GHRP Comparison
| Peptide | GH Release | Cortisol | Prolactin | Hunger |
|---|---|---|---|---|
| Ipamorelin | +++ | - | - | - |
| GHRP-6 | +++ | + | + | +++ |
| GHRP-2 | ++++ | ++ | ++ | ++ |
| Hexarelin | ++++ | ++ | ++ | + |
References
- Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998.
- Johansen PB, et al. "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." Growth Horm IGF Res. 1999.
- Beck DE, et al. "Prospective, randomized, controlled, proof-of-concept study of the safety and efficacy of ipamorelin." J Gastrointest Surg. 2017.